Date: 2012-07-16
Type of information: R&D agreement
Compound: therapeutic antibodies
Company: ImmunoGenes (Switzerland-Hungary) NYU’s Feske Lab (USA)
Therapeutic area: Autoimmune diseases - Infectious diseases
Type agreement: R&D
development
Action mechanism:
Disease: autoimmune diseases, infectious diseases
Details: ImmunoGenes AG and NYU School of Medicine have announced the initiation of a collaboration between ImmunoGenes and NYU’s Feske Lab focused on the development of therapeutic antibodies for the treatment of autoimmune disorders and infectious diseases. Under the collaboration, The Feske Lab will identify key targets in calcium release activated calcium (CRAC) channels, and ImmunoGenes will generate antibodies against those targets using its proprietary FcRn-overexpressing transgenic (tg) mice. The Feske Lab has previously published extensively on the role of CRAC channel function mediated by ORAI and STIM proteins in generating pro-inflammatory effector T cell function in autoimmunity. Similarly, ImmunoGenes has previously published at length on the ability of its FcRn tg mice to generate antibodies against difficult targets as a result of their improved antigen presentation and generation of increased antibody diversity.
Financial terms:
Latest news:
